Medications for Lipid Control: Statins vs Newer Drugs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39111897/
In the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), statins are the primary pharmacologic intervention for ASCVD risk reduction. Statins have proven efficacy and safety in reducing cardiovascular...
Statins are key for ASCVD prevention, with proven efficacy. Alternative therapies like ezetimibe and PCSK9 inhibitors, along with emerging treatments, enhance lipid management and cardiovascular outcomes.
Share
PCSK9 inhibition: from effectiveness to cost-effectiveness
Source : https://pubmed.ncbi.nlm.nih.gov/38988669/
Dyslipidaemia is a complex disorder characterised by abnormal lipid levels in the blood, including cholesterol and triglycerides, and plays an important role in the development of atherosclerotic cardiovascular disease. Most...
PCSK9 inhibitors are effective in lowering LDL cholesterol and offer significant benefits for high-risk patients. Despite high costs and mixed cost-effectiveness results, they remain a valuable treatment option.
Share
Lipid levels and risk of acute pancreatitis using bidirectional Mendelian randomization
Source : https://pubmed.ncbi.nlm.nih.gov/38491158/
Previous studies found lipid levels, especially triglycerides (TG), are associated with acute pancreatitis, but their causalities and bi-directions were not fully examined. We determined whether abnormal levels of TG, high-density...
Higher triglycerides are a risk factor for acute pancreatitis, while lower HDL-C is both a risk factor and a consequence. HDL-C modulation may aid in prevention and treatment.
Share
Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1
Source : https://pubmed.ncbi.nlm.nih.gov/38710625/
Familial hypobetalipoproteinemia (FHBL) 1 is a rare genetic disorder with an autosomal codominant mode of inheritance and is caused by defects in the apolipoprotein (apo) B (APOB) gene that disable...
Familial hypobetalipoproteinemia 1 (FHBL1) is a rare genetic disorder impairing lipoprotein formation, causing hypolipidemia and fat malabsorption, leading to severe complications. Treatment is primarily palliative.
Share
Recent Treatment Strategies for Acute Pancreatitis
Source : https://pubmed.ncbi.nlm.nih.gov/38398290/
Acute pancreatitis (AP) is a leading gastrointestinal disease that causes hospitalization. Initial management in the first 72 h after the diagnosis of AP is pivotal, which can influence the clinical...
Acute pancreatitis (AP) management involves assessing severity, fluid resuscitation, pain control, and ERCP for gallstone cases. Hypertriglyceridemia management is crucial in AP treatment to prevent recurrence.
Share